While local HN expression levels did not show any correlation with GBM patient progression or survival (Figure 7C), tumor FPR2 expression was associated with a worse prognosis, since patients with higher levels of FPR2 exhibited a reduced progression-free interval (PFI) and lower overall survival (OS) (Figure 7D). The gene discussed is FPR2; the disease is glioblastoma.